Results 251 to 260 of about 945,377 (287)
Some of the next articles are maybe not open access.
Muscle type and fiber type specificity in muscle wasting
The International Journal of Biochemistry & Cell Biology, 2013Muscle wasting occurs in a variety of conditions, including both genetic diseases, such as muscular dystrophies, and acquired disorders, ranging from muscle disuse to cancer cachexia, from heart failure to aging sarcopenia. In most of these conditions, the loss of muscle tissue is not homogeneous, but involves specific muscle groups, for example ...
CICILIOT, STEFANO +4 more
openaire +4 more sources
Muscle wasting in chronic kidney disease
Pediatric Nephrology, 2017Loss of lean body mass is a relevant component of the cachexia, or protein energy wasting (PEW), syndrome. Reduced muscle mass seems to be the most solid criterion for the presence of cachexia/PEW in patients with chronic kidney disease (CKD), and those with greater muscle mass loss have a higher risk of death.
Eduardo A. Oliveira +3 more
openaire +2 more sources
Control of ubiquitination in skeletal muscle wasting
The International Journal of Biochemistry & Cell Biology, 2005The ubiquitin proteasome system is now well recognized to play a role in mediating skeletal muscle protein wasting. Ubiquitin exerts its effects by covalent attachment to other proteins. Increased ubiquitination of muscle proteins has been observed in a number of conditions of atrophy suggesting that flux through the pathway may be regulated by ...
openaire +2 more sources
Current Opinion in Clinical Nutrition and Metabolic Care, 2014
Cirrhosis is the result of the progression of necroinflammatory liver diseases leading to fibrosis, portal hypertension, and a catabolic state, which might cause muscle wasting or sarcopenia. In this review, we analyze the methods for muscularity assessment, the incidence and clinical impact of muscle wasting, and potential novel therapeutic strategies
openaire +2 more sources
Cirrhosis is the result of the progression of necroinflammatory liver diseases leading to fibrosis, portal hypertension, and a catabolic state, which might cause muscle wasting or sarcopenia. In this review, we analyze the methods for muscularity assessment, the incidence and clinical impact of muscle wasting, and potential novel therapeutic strategies
openaire +2 more sources
Muscle wasting: emerging pathways and potential drug targets
Trends in Pharmacological Sciences, 2023Serkan Kir, Şevval Nur Bilgic
exaly
Prescrire international, 2012
Sorafenib inhibits multiple kinases involved in angiogenesis and tumour growth. It is used for second-line treatment of advanced kidney cancer and some forms of liver cancer. A placebo-controlled trial in 80 patients with metastatic kidney cancer showed a statistically significant increase in muscle loss during sorafenib therapy.
openaire +1 more source
Sorafenib inhibits multiple kinases involved in angiogenesis and tumour growth. It is used for second-line treatment of advanced kidney cancer and some forms of liver cancer. A placebo-controlled trial in 80 patients with metastatic kidney cancer showed a statistically significant increase in muscle loss during sorafenib therapy.
openaire +1 more source
Proceedings of the National Academy of Sciences of the United States of America, 2023
Aneesha Dasgupta +2 more
exaly
Aneesha Dasgupta +2 more
exaly